Safety and drug level study of PMC-309 in advanced tumors
Part of Cancer clinical trials.
This Phase 1 trial tests how safe PMC-309 is and how the drug behaves in the body (blood levels) in people with advanced or metastatic solid tumors. Because it’s an early study, the main goal is to find safe dosing and gather information that could guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and sign a consent form willingly.
- Have advanced or metastatic solid cancer (not lymphoma) that cannot be fully removed and has come back or not responded to prior treatment.
- Have cancer that has grown after anti–PD-1/PD-L1 treatment (and meet the trial’s specific timing and scan rules).
- Have measurable tumors on CT or MRI, and you can have them re-scanned during screening if needed.
- Be well enough to do daily activities most of the time (ECOG 0–1).
- Have blood counts, liver, and kidney test results within required limits (checked within 7 days of screening).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
This Phase 1 trial tests PM54, a study drug, in people with advanced (cancer that has spread) solid tumors when standard treatments are no longer working. It focuses on safety and early signs of how well the treatment may work in specific cancer types.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.